Effects of fluticasone and vilanterol oral inhalation: A Synthesis of Findings from 9 Studies

  1. Home
  2. Effects of fluticasone and vilanterol oral inhalation
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of fluticasone and vilanterol oral inhalation: A Synthesis of Findings from 9 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of fluticasone and vilanterol oral inhalation: A Synthesis of Findings from 9 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Fluticasone furoate/vilanterol (FF/VI) is a combination medication used for the treatment of asthma and COPD. It combines a long-acting beta2-agonist (LABA), vilanterol, with an inhaled corticosteroid (ICS), fluticasone furoate. 8 Vilanterol acts by relaxing the muscles in the airways, making it easier to breathe. 8 Fluticasone furoate reduces airway inflammation and hyper-responsiveness. 8 Studies have shown that FF/VI can improve lung function and reduce symptoms in patients with asthma and COPD. 2 5 FF/VI is designed for once-daily administration, offering a simplified dosing schedule compared to other ICS/LABA combinations. 3 4 In healthy subjects, FF/VI has not been found to prolong the QT interval, a measure of heart function. 7

Benefits and Risks

Benefit Summary

FF/VI has shown promise in improving lung function, reducing symptoms, and potentially improving patient adherence due to its once-daily dosing schedule. 2 5 3 9

Risk Summary

Potential risks associated with FF/VI include oral candidiasis, dysphonia, and an increased risk of pneumonia. 5 3 Additionally, high doses of fluticasone furoate may lead to adrenal suppression. 2

Comparison of Studies

Commonalities

These studies all investigated the efficacy and safety of FF/VI in the treatment of respiratory conditions such as asthma and COPD. They consistently showed improvements in lung function and symptom reduction.

Differences

The studies differed in their specific focus, study design, and endpoints. For instance, 8 explored the mechanism of action of FF/VI in asthma treatment, while 5 assessed its efficacy and safety in COPD patients. Some studies compared FF/VI to placebo, 5 , while others did not conduct direct comparisons with other ICS/LABA combinations. 3

Consistency and Contradictions in Results

While the studies generally support the efficacy of FF/VI in managing respiratory conditions, there is variability in the observed effects and safety profiles. The studies did not all directly compare FF/VI to other ICS/LABA combinations. 3 Further research is needed to establish the optimal use of FF/VI and compare it to existing treatments.

Real-World Application Considerations

FF/VI can be a valuable treatment option for patients with asthma and COPD, but it is important to be aware of potential side effects and risks. These include oral candidiasis, dysphonia, and an increased risk of pneumonia. 5 3 High doses of fluticasone furoate may lead to adrenal suppression. 2 Proper use as directed by a healthcare professional is crucial to minimize potential risks and maximize the benefits of this medication.

Limitations of Current Research

The current research on FF/VI has certain limitations. For instance, the studies may not be generalizable to all populations due to differences in study participants and their characteristics. Further research is needed to assess long-term efficacy and safety, as well as to conduct direct comparisons to other existing ICS/LABA combinations.

Future Research Directions

Future research on FF/VI should focus on comparative studies against other available ICS/LABA medications to determine its relative efficacy and safety. Additionally, long-term studies are needed to assess its long-term benefits, risks, and potential for adverse effects.

Conclusion

FF/VI has shown promise in managing respiratory conditions such as asthma and COPD, offering improvements in lung function and symptom reduction. Its once-daily administration may improve patient adherence to treatment regimens. However, ongoing research is necessary to comprehensively assess its long-term effects, safety, and optimal use compared to other available ICS/LABA treatments. If you are considering using FF/VI, it is essential to consult with a healthcare professional to determine if it is appropriate for you and to discuss any potential risks and side effects.

Literature analysis of 9 papers
Positive Content
9
Neutral Content
0
Negative Content
0
Article Type
4
1
1
4
9
1.

Ocufen (flurbiprofen) in the treatment of ocular pain after radial keratotomy.

Author: GwonA, VaughanE R, CheethamJ K, DeGryseR

No effect on corneal sensation
Relieves ocular pain
Transient burning

Topical 0.03% flurbiprofen ophthalmic solution effectively and safely relieved ocular pain without affecting corneal sensation, providing an alternative to systemic analgesics.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.

Author: WolthersOle D

Asthma treatment

This paper reviews the pharmacokinetics and systemic activity of fluticasone fumarate/vilanterol trifenatate, a new inhaled treatment for asthma. It summarizes efficacy data in children, adolescents and adults with asthma.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.

Author: MateraMaria Gabriella, CapuanoAnnalisa, CazzolaMario

COPD treatment
Pneumonia risk

Fluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed dose combination that allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment. FF/VI is delivered via a novel, single-step activation, multi-dose dry powder inhaler for oral inhalation, Ellipta.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate.

Author: AllenAnn, BareillePhilippe J, RousellVicki M

Anti-inflammatory effect
Once-daily efficacy

Fluticasone furoate (FF) is a new inhaled corticosteroid for asthma and COPD. It stays in the lungs for a long time, providing continuous benefit. FF's ability to bind to the glucocorticoid receptor and remain in the lungs suggests greater and longer-lasting anti-inflammatory effects, potentially leading to better once-daily treatment options.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.

Author: BusseWilliam W, BleeckerEugene R, BatemanEric D, LötvallJan, ForthRichard, DavisAngela M, JacquesLoretta, HaumannBrett, WoodcockAshley

Asthma treatment
Oral candidiasis

Fluticasone furoate (FF), a novel inhaled corticosteroid, demonstrated efficacy in treating patients with persistent moderate-to-severe asthma, with no dose-response relationship observed across the tested doses.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.

Author: KempsfordRodger, AllenAnn, KellyKathryn, SagguParminder, CrimCourtney

QT prolongation

Fluticasone furoate (FF)/vilanterol (VI) at the highest therapeutic strength (200/25 μg) is not associated with QTc prolongation in healthy subjects.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Vilanterol and fluticasone furoate for asthma.

Author: DwanKerry, MilanStephen J, BaxLynne, WaltersNicola, PowellColin

Asthma control

Vilanterol (VI) is a long-acting beta<sub>2</sub>-agonist (LABA) that can improve asthma symptoms, lung function, and reduce exacerbations. While other LABAs are twice-daily medications, VI is a once-daily therapy. Fluticasone furoate (FF) is an inhaled corticosteroid (ICS), and ICS therapy is recommended for asthma patients who need a "reliever" medication three or more times per week. Currently, only one once-daily ICS/LABA combination (FF/VI) is available.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.

Author: SliwkaAgnieszka, JankowskiMilosz, Gross-SondejIwona, StormanMonika, NowobilskiRoman, BalaMalgorzata M

COPD Treatment
Patient Adherence

Combining long-acting beta₂-agonists (LABA) and long-acting muscarinic antagonists (LAMA) in a single inhaler device provides convenient once-daily dosing for managing chronic obstructive pulmonary disease (COPD), potentially improving patient adherence to treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.